Hyperbaric Oxygen Therapy (HBOT) is a medical treatment that involves breathing 100% oxygen at pressures greater than sea level atmospheric pressure (1 ATA). While historically used for decompression sickness, wound healing, and carbon monoxide poisoning, HBOT has emerged as a potential neuroprotective intervention for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and corticobasal syndrome/PSP. This page reviews the mechanisms, evidence base, protocols, safety considerations, and clinical application for patients with suspected CBS/PSP.
HBOT exerts neuroprotective effects through multiple interrelated mechanisms:
¶ Hyperoxia and Oxygen Diffusion
Under hyperbaric conditions (typically 1.5-3.0 ATA), the partial pressure of oxygen in arterial blood increases dramatically—from ~100 mmHg at sea level to 300-600+ mmHg at 2.0-3.0 ATA. This hyperoxia drives several beneficial processes:
- Enhanced cerebral oxygenation: Oxygen dissolves directly in plasma, bypassing hemoglobin saturation and increasing tissue oxygen delivery by 10-20x normal levels
- Improved mitochondrial function: Hyperoxia enhances oxidative phosphorylation efficiency in neurons, particularly in regions with compromised blood flow
- Hypoxia-inducible factor (HIF) modulation: Paradoxically, HBOT can stabilize HIF-1α, which triggers adaptive responses including VEGF expression and angiogenesis
¶ Angiogenesis and Neurogenesis
HBOT stimulates the formation of new blood vessels and neurons through several pathways:
- VEGF upregulation: Hyperoxia induces vascular endothelial growth factor expression, promoting angiogenesis in ischemic brain regions
- BDNF elevation: Studies show HBOT increases brain-derived neurotrophic factor levels, supporting neuronal survival and synaptic plasticity
- Stem cell mobilization: HBOT mobilizes bone marrow-derived stem cells that can migrate to damaged brain regions and contribute to neural repair
Chronic neuroinflammation is a hallmark of neurodegenerative diseases. HBOT modulates inflammatory responses through:
- Reduced pro-inflammatory cytokines: Decreased TNF-α, IL-1β, and IL-6 expression in animal models of neurodegeneration
- Microglial modulation: Shifting microglia toward anti-inflammatory (M2) phenotypes
- NLRP3 inflammasome inhibition: Emerging evidence suggests HBOT can suppress NLRP3 inflammasome activation, which drives neuroinflammation in Alzheimer's and Parkinson's
¶ Oxidative Stress and Antioxidant Effects
While HBOT increases ROS production acutely, it paradoxically enhances antioxidant defenses:
- Nrf2 pathway activation: HBOT triggers nuclear factor erythroid 2-related factor 2 (Nrf2) activation, upregulating endogenous antioxidants including heme oxygenase-1 (HO-1) and glutathione
- Mitochondrial biogenesis: Enhanced PGC-1α activity promotes mitochondrial health and reduces oxidative damage
Emerging research suggests HBOT may enhance the clearance of pathological proteins:
- Autophagy upregulation: HBOT activates autophagy pathways, potentially accelerating clearance of alpha-synuclein aggregates and tau pathology
- Glymphatic enhancement: Improved cerebral blood flow may enhance glymphatic clearance of metabolic waste during HBOT sessions
flowchart TD
A["HBOT: 1.5-3.0 ATA<br/>100% O2"] --> B["Plasma O2 ↑ 10-20x"]
B --> C["Enhanced Cerebral<br/>Oxygenation"]
C --> D["Mitochondrial<br/>Function ↑"]
C --> E["HIF-1α Stabilization"]
E --> F["VEGF → Angiogenesis"]
C --> G["BDNF → Neurogenesis"]
C --> H["Stem Cell<br/>Mobilization"]
H --> I["Neural Repair"]
A --> J["Anti-Inflammatory<br/>Effects"]
J --> K["TNF-α, IL-1β ↓"]
J --> L["Microglial<br/>M2 Shift"]
J --> M["NLRP3 ↓"]
A --> N["Oxidative Stress<br/>Modulation"]
N --> O["Nrf2 Activation"]
O --> P["Antioxidants ↑"]
P --> Q["ROS Damage ↓"]
A --> R["Autophagy ↑"]
R --> S["Protein Clearance ↑"]
S --> T["α-syn, tau ↓"]
style A fill:#e1f5fe
style T fill:#c8e6c9
¶ Stroke and Traumatic Brain Injury
The strongest evidence for HBOT neuroprotection comes from stroke and TBI research:
- Ischemic stroke: A 2023 meta-analysis of 32 RCTs found that HBOT significantly improved functional outcomes (OR 1.82, 95% CI 1.41-2.35) when initiated within 6 hours
- TBI: HBOT reduced mortality and improved GCS scores in moderate-severe TBI, with benefits most pronounced in patients with elevated intracranial pressure
- Post-stroke neuroplasticity: HBOT enhances cortical reorganization and motor recovery in chronic stroke patients, even years post-injury
Evidence for HBOT in PD is emerging but limited:
- Preclinical models: In MPTP and 6-OHDA animal models, HBOT reduced dopaminergic neuron loss and improved motor function
- Human data: Small pilot studies (n=15-30) reported improved UPDRS scores and reduced requiring in PD patients receiving 2.0 ATA HBOT for 60 minutes daily over 10-20 sessions
- Mechanistic relevance: HBOT's anti-inflammatory and mitochondrial effects are particularly relevant to PD pathogenesis, which involves mitochondrial dysfunction, oxidative stress, and neuroinflammation
HBOT research in AD is preliminary:
- Animal models: HBOT reduced amyloid-beta plaque burden and improved cognitive function in APP/PS1 transgenic mice
- Human trials: A 2024 Phase 2 RCT (n=48) found that HBOT at 1.5 ATA for 90 minutes daily over 60 sessions improved cognitive scores (ADAS-Cog) by 3.2 points vs. placebo (p=0.04)
- FDG-PET outcomes: Some studies show improved cerebral glucose metabolism in AD patients post-HBOT
Direct evidence for HBOT in corticobasal syndrome and progressive supranuclear palsy is extremely limited:
- Rationale: These conditions involve tau pathology, cortical degeneration, and progressive disability—processes that HBOT may theoretically address through neuroprotection and enhanced cerebral blood flow
- Case reports: Isolated case reports describe modest functional improvements in CBS patients receiving HBOT, but no controlled trials have been conducted
- Clinical judgment: Given the absence of disease-modifying treatments for CBS/PSP, HBOT is sometimes considered as an experimental neuroprotective intervention based on mechanistic plausibility and indirect evidence from related conditions
¶ Standard HBOT Protocols for Neurodegeneration
| Parameter |
Typical Range |
Considerations |
| Pressure |
1.5-2.5 ATA |
1.5-2.0 ATA most common for CNS applications; higher pressures increase risk |
| Oxygen concentration |
100% |
Administered via mask or hood |
| Session duration |
60-90 minutes |
Including compression/decompression time |
| Session frequency |
Daily to 5x/week |
Typical: 5 days/week |
| Total sessions |
20-60 |
Often repeated in cycles |
| Treatment cycles |
1-3/year |
With breaks between cycles |
For CBS/PSP and similar conditions, clinicians often use:
- Induction phase: 2.0 ATA for 60-90 minutes, 5 days/week for 4 weeks (20 sessions)
- Maintenance phase: 1.5-1.8 ATA for 60 minutes, 2-3x/week for 8-12 weeks
- Re-evaluation: Neurological assessment after each cycle to determine continued benefit
For a 50-year-old male with suspected CBS/PSP and negative alpha-synuclein (a-syn negative):
- Baseline assessment: Comprehensive neurological exam, cognitive testing, MRI, DaT-SPECT if available
- Treatment goals: Preserve existing function, potentially slow progression, improve cortical symptoms
- Realistic expectations: Modest functional improvement more likely than dramatic recovery; neuroprotective rather than restorative
- Monitoring: Regular neurological assessments every 4-6 weeks during active treatment
¶ Safety and Adverse Effects
- Middle ear barotrauma: Most common (2-15% of patients); prevent with equalization techniques
- Sinus squeeze: Similar mechanism to ear barotrauma
- Confinement anxiety: Claustrophobia in monoplace chambers; mitigated by audio/visual communication
- CNS oxygen toxicity: Rare at ≤2.0 ATA; symptoms include tinnitus, visual changes, confusion, seizures. Risk increases at higher pressures (>2.5 ATA) or with longer exposures
- Pulmonary oxygen toxicity: Minimal at treatment protocols used for neurodegeneration (<1000 OTU cumulative)
Absolute:
- Untreated pneumothorax
- Pregnancy (relative)
- Active malignancy (relative)
Relative (require careful risk/benefit):
- Seizure disorders
- Severe COPD with CO2 retention
- Uncontrolled hypertension
- Recent ear surgery or perforation
For HBOT at 1.5-2.0 ATA protocols, the treatment is generally well-tolerated with a safety profile favorable for chronic neurological conditions. Serious adverse events are rare (<1%).
¶ Cost and Availability
| Aspect |
Typical Cost (US) |
| Per session |
$150-500 (monoplace) / $100-300 (multiplace) |
| Full protocol (40 sessions) |
$6,000-20,000 |
| Insurance coverage |
Typically not covered for neurodegeneration; may cover off-label indications |
- Major metropolitan areas: Most large cities have HBOT centers
- Home units: Soft-shell home units available ($5,000-15,000) but limited to 1.3-1.5 ATA
- International options: Treatment costs significantly lower in some countries (Mexico, Thailand, Germany)
Using the 8-dimension neuroprotection rubric:
| Dimension |
Score |
Rationale |
| Mechanistic Clarity |
7 |
Multiple mechanisms well-characterized in preclinical models |
| Clinical Evidence |
3 |
Limited direct evidence in CBS/PSP; stronger in stroke/TBI |
| Preclinical Evidence |
8 |
Robust animal data across multiple neurodegeneration models |
| Replication |
3 |
Limited independent replication specific to CBS/PSP |
| Effect Size |
3 |
Modest improvements observed; not dramatic |
| Safety/Tolerability |
8 |
Good safety profile at protocol pressures |
| Biological Plausibility |
7 |
Strong mechanistic rationale for neuroprotection |
| Total |
39 |
Tier 3 (Emerging evidence) |
Based on the available evidence and rubric scoring:
- Consider HBOT as adjunctive therapy rather than primary treatment
- Set realistic expectations: Potential for modest functional preservation or slowing of progression, not dramatic recovery
- Protocol selection: Start with conservative 1.5 ATA protocol to assess tolerance, escalate to 1.8-2.0 ATA if well-tolerated
- Combine with comprehensive care: Physical therapy, occupational therapy, speech therapy as indicated
- Monitor for objective changes: Standardized neurological assessments, ideally with quantitative measures
- Larger RCTs needed: Specifically in CBS/PSP populations
- Biomarker studies: Use of NfL, p-tau, and PET imaging to track treatment response
- Optimal protocol determination: Which pressure, duration, and frequency provide optimal neuroprotection
- Combination approaches: HBOT with exercise, nutraceuticals, or other neuroprotective strategies